IGF1 and cancer: A variety of IGF-1/IGF-1R inhibitors have entered clinical development in the cancer field [244,245,246,247,248], including IGF-1-R tyrosine kinase inhibitors (including sorafenib) and mAbs against IGF-1-R and IGF-1.